ADAM17 is required for EGF-R–induced intestinal tumors via IL-6 trans-signaling

Colorectal cancer is treated with antibodies blocking epidermal growth factor receptor (EGF-R), but therapeutic success is limited. EGF-R is stimulated by soluble ligands, which are derived from transmembrane precursors by ADAM17-mediated proteolytic cleavage. In mouse intestinal cancer models in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Stefanie, Schumacher, Neele, Schwarz, Jeanette, Tangermann, Simone, Kenner, Lukas, Schlederer, Michaela, Sibilia, Maria, Linder, Markus, Altendorf-Hofmann, Annelore, Knösel, Thomas, Gruber, Elisabeth S., Oberhuber, Georg, Bolik, Julia, Rehman, Ateequr, Sinha, Anupam, Lokau, Juliane, Arnold, Philipp, Cabron, Anne-Sophie, Zunke, Friederike, Becker-Pauly, Christoph, Preaudet, Adele, Nguyen, Paul, Huynh, Jennifer, Afshar-Sterle, Shoukat, Chand, Ashwini L., Westermann, Jürgen, Dempsey, Peter J., Garbers, Christoph, Schmidt-Arras, Dirk, Rosenstiel, Philip, Putoczki, Tracy, Ernst, Matthias, Rose-John, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881468/
https://www.ncbi.nlm.nih.gov/pubmed/29472497
http://dx.doi.org/10.1084/jem.20171696

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881468/
https://www.ncbi.nlm.nih.gov/pubmed/29472497
http://dx.doi.org/10.1084/jem.20171696

Ejemplares similares